-
Most postmenopausal women who suffer a fracture do not receive treatment for osteoporosis.
-
The FDA has approved the first drug for the treatment of moderate-to-severe Alzheimers disease. Memantine, a noncompetitive inhibitor of the N-methyl-D-aspartate receptor, has been available outside of the United States since 1982.
-
Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis; Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis; Exercise Testing to Predict Cardiovascular and All-Cause Death in Women
-
Exercise reduces the risk of breast cancer after menopause. Although the exercise need not be strenuous, longer duration of exercise confers greater benefit.
-
Treatment of CAP with 750 mg of levofloxacin daily for 5 days was as effective as a 10-day course of 500 mg daily.
-
The 12-lead ECG and accompanying lead II rhythm strip in the Figure were obtained from a 74-year-old man with sever pulmonary disease. The computer interpreted this tracing as showing normal sinus rhythm. Do you agree?
-
-
A generic form of paroxetine (PaxilGlaxoSmithKline) will soon be on the market. The drug marks the second SSRI antidepressant to go generic after fluoxetine (Prozac) last year.
-
The objective of this monograph is to provide an overview of the scope of allergic disorders, and review the current understanding of the mechanism of the allergic response. Due to the extensive nature of the topic, we will limit our discussion to systemic reactions eliciting an IgE-mediated response. Further, the intimate relationship between organs involved will be reviewed, particularly the relationship between allergic rhinitis and asthma. Part I includes the current evaluation, including historical features, exposures, physical exam findings, and ancillary diagnostic options will be reviewed.
-
The FDA has approved Pfizer's eplerenone (Inspra) for the treatment of congestive heart failure (CHF) in patients who have sustained a myocardial infarction.
